21.2 C
New York
Thursday, June 18, 2026

Tag: methodology

newssourceFORcompanyinformationcontent1marketreleases

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Cognex Reports Second Quarter 2025 Results

NATICK, Mass., July 30, 2025 /PRNewswire/ -- Cognex Corporation (NASDAQ: CGNX), the global technology leader in industrial machine vision, today reported financial results for the...

Kite Realty Group Reports Second Quarter 2025 Operating Results

INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, reported today its operating results for the second quarter ended June 30, 2025. For the quarters ended June 30, 2025 and 2024, net income attributable to common shareholders was $110.3 million, or $0.50 per diluted share, compared to a net loss of $48.6 million, or $0.22 per diluted share, respectively. For the six months ended June 30, 2025 and 2024, net income attributable to common shareholders was $134.0 million, or $0.61 per diluted share, compared to a net loss of $34.5 million, or $0.16 per diluted share, respectively.

Invesco Canada announces risk rating changes to Canadian mutual funds

TORONTO, July 30, 2025 /CNW/ -- Invesco Canada Ltd. today announced risk rating changes to two of its mutual funds. The changes are effective...

Banque Fédérative du Crédit Mutuel – 2025 half-year results press release

First half of 2025:
very strong business activity and solid results,
penalized by the non-recurring income tax surcharge

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

EcoSynthetix Reports 2025 Second Quarter Results

BURLINGTON, ON, July 29, 2025 /CNW/ - EcoSynthetix Inc. (TSX: ECO) ("EcoSynthetix" or the "Company"), a renewable chemicals company that produces a portfolio of commercially...

Avis Budget Group Reports Second Quarter Results

PARSIPPANY, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for second quarter 2025 today. We ended the quarter with revenues of $3.0 billion, net income of $5 million, and Adjusted EBITDA1 of $277 million.

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of...

ARKEMA COMPLETES ISCC PLUS CERTIFICATION FOR ALL ACRYLIC MONOMER FACILITIES WORLDWIDE

BAYPORT, Texas, July 29, 2025 /PRNewswire/ -- Arkema, a leader in specialty materials, has earned ISCC PLUS certification for acrylic monomers at all of...

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMethodology

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers